News

Morning Read: MU good for the bottom line, Cardinal Health facility banned from selling controlled substances

Meaningful use was great for the bottom line of for-profit hospitals in 2011 and Fitch Ratings expects the incentives to be larger this year and next. The firm’s quarterly diagnosis report found that meaningful use incentive checks added a cumulative $396 million in earnings before interest, taxes, debt and amortization. The Council for Affordable Health […]

Meaningful use was great for the bottom line of for-profit hospitals in 2011 and Fitch Ratings expects the incentives to be larger this year and next. The firm’s quarterly diagnosis report found that meaningful use incentive checks added a cumulative $396 million in earnings before interest, taxes, debt and amortization.

The Council for Affordable Health Insurance reports that there are 2,262 laws at the state level that address what treatments and medications health insurance must cover. Treatments for cancer, autism, and diabetes are frequently addressed by mandates. At least 30 states now require that the financial impact of a coverage requirement be analyzed before the rule is passed.

Cardinal Health is banned from selling controlled substance medications from its Florida distribution center for two years because of allegations of selling to “rogue” Internet pharmacies. As part of the agreement with the Drug Enforcement Administration, Cardinal admitted its due diligence efforts were not strong enough and allowed it to sell more than 12 million dosage units of oxycodone to four area pharmacies in just three years.

Piramal Healthcare in India spent $635 million to buy Decision Resources Group which provides reports, specialized databases and consulting services focused on drug utilization and projections in multiple therapeutic areas to biotech companies. Decision Resources will operate as a standalone company and expects $160 million in revenue in 2012 from market segments valued at $2.5 billion.

The Ozcan Research Group at UCLA has developed a a digital reader for all rapid diagnostic tests (RDTs), such as home pregnancy tests, even drug and STD tests that attaches to smartphones. A commercial version of this reader would allow cost-effective large scale use of RDTs for better health care delivery as well as monitoring and geo-tracking of emerging epidemics.Professor Aydogan Ozcan has secured $2.5 million seed funding and  $383K from the National Institute of Health small business innovation research program, for his startup Holomic.
presented by